Loading stock data…
NeoGenomics (NEO)
$14.25+0.08 (+0.56%)
Market ClosedLast close Jun 29
NeoGenomics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NeoGenomics, Inc. in the Healthcare sector is trading at $14.25 with a market capitalization of $1.4B. Wall Street consensus targets $15.06 (9 analysts), implying a +5.7% move over the next 12 months. The stock is currently near its 52-week high of $14.48, remaining 40.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +5.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $186.67M↓ | $190.17M↑ | $187.80M↑ | $181.33M↑ | $168.03M |
| Gross Profit | $80.86M↓ | $83.34M↑ | $80.45M↑ | $77.26M↑ | $73.25M |
| Operating Income | -$18.24M↓ | -$12.79M↑ | -$19.93M↑ | -$27.59M↑ | -$27.82M |
| Net Income | -$17.11M↓ | -$9.88M↑ | -$27.13M↑ | -$45.09M↓ | -$25.92M |
Peer Comparison
JNJUNHPFE
Fundamentals
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical compani...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.97%
Volume
Today's trading volume
2.23M
Recent News
A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
Looking back on testing & diagnostics services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including NeoGenomics (NASDAQ:NEO) and its peers.
1 Unprofitable Stock for Long-Term Investors and 2 Facing Headwinds
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is NeoGenomics (NEO) Using Its ASCO ctDNA Focus To Redefine Its Precision Oncology Edge?
Earlier in May 2026, NeoGenomics, Inc. announced it would present eight scientific abstracts at the 2026 ASCO Annual Meeting in Chicago, highlighting advances in hematologic malignancy testing, solid-tumor profiling, and molecular residual disease through circulating tumor DNA. The company is also using this ASCO presence to showcase new biomarkers for biopharma partners and unveil an updated mission centered on more personalized cancer treatment decisions, underscoring its push deeper into...
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years. Healthcare companies, drug makers, hospitals, and insurers, earn revenue from clinical services and product sales.